Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Solifenacin/Mirabegron FDC vs Co-administration
NCT02010944Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2012
- Primary completion
- Nov 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of solifenacin and mirabegron in overactive bladder (OAB) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum concentration of solifenacin in plasma, AUC until last sample taken of solifenacin in plasma and 4 more. Started Sep 2012; status: completed.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02010944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02010944.